TriSalus Life Sciences (TLSI) Competitors $5.13 -0.59 (-10.31%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSI vs. AXGN, IRMD, EMBC, BVS, RXST, SIBN, AVNS, BFLY, CBLL, and KIDSShould you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include AxoGen (AXGN), Iradimed (IRMD), Embecta (EMBC), Bioventus (BVS), RxSight (RXST), SI-BONE (SIBN), Avanos Medical (AVNS), Butterfly Network (BFLY), CeriBell (CBLL), and OrthoPediatrics (KIDS). These companies are all part of the "medical equipment" industry. TriSalus Life Sciences vs. AxoGen Iradimed Embecta Bioventus RxSight SI-BONE Avanos Medical Butterfly Network CeriBell OrthoPediatrics TriSalus Life Sciences (NASDAQ:TLSI) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment. Do analysts prefer TLSI or AXGN? TriSalus Life Sciences currently has a consensus target price of $11.56, indicating a potential upside of 125.39%. AxoGen has a consensus target price of $22.60, indicating a potential upside of 38.91%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than AxoGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TriSalus Life Sciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20AxoGen 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, TLSI or AXGN? TriSalus Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Which has better earnings and valuation, TLSI or AXGN? AxoGen has higher revenue and earnings than TriSalus Life Sciences. AxoGen is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTriSalus Life Sciences$29.43M5.32-$59.04M-$1.33-3.86AxoGen$187.34M3.85-$21.72M-$0.22-73.95 Does the media favor TLSI or AXGN? In the previous week, AxoGen had 3 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 7 mentions for AxoGen and 4 mentions for TriSalus Life Sciences. AxoGen's average media sentiment score of 1.33 beat TriSalus Life Sciences' score of 1.19 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer TLSI or AXGN? AxoGen received 443 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 72.89% of users gave AxoGen an outperform vote. CompanyUnderperformOutperformTriSalus Life SciencesOutperform Votes14100.00% Underperform VotesNo VotesAxoGenOutperform Votes45772.89% Underperform Votes17027.11% Is TLSI or AXGN more profitable? AxoGen has a net margin of -7.91% compared to TriSalus Life Sciences' net margin of -206.24%. TriSalus Life Sciences' return on equity of 0.00% beat AxoGen's return on equity.Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences-206.24% N/A -236.83% AxoGen -7.91%-14.91%-7.49% Do insiders & institutionals have more ownership in TLSI or AXGN? 2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 32.8% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 7.0% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAxoGen beats TriSalus Life Sciences on 10 of the 19 factors compared between the two stocks. Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSI vs. The Competition Export to ExcelMetricTriSalus Life SciencesSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$156.43M$4.38B$5.57B$7.83BDividend YieldN/A39.98%5.11%4.22%P/E Ratio-2.0630.6722.4418.48Price / Sales5.3254.91394.09103.59Price / CashN/A51.0838.1834.62Price / Book-5.236.116.774.25Net Income-$59.04M$68.15M$3.22B$248.23M7 Day Performance-9.20%-0.12%1.49%0.89%1 Month Performance-6.73%-2.24%4.00%3.53%1 Year Performance-44.90%24.15%16.21%5.08% TriSalus Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSITriSalus Life Sciences3.7659 of 5 stars$5.13-10.3%$11.56+125.4%-44.9%$156.43M$29.43M-2.06106News CoveragePositive NewsGap DownAXGNAxoGen2.8864 of 5 stars$15.18-2.5%$22.60+48.9%+153.8%$673.14M$187.34M-47.44450Positive NewsIRMDIradimed4.8351 of 5 stars$50.78-1.9%$72.00+41.8%+29.1%$645.67M$73.24M33.85110Positive NewsEMBCEmbecta4.5847 of 5 stars$10.91-3.8%$20.33+86.4%+20.3%$634.24M$1.11B10.911,900Positive NewsBVSBioventus3.298 of 5 stars$7.50-4.1%$15.00+100.0%+84.6%$614.58M$573.28M-12.291,200Positive NewsRXSTRxSight2.8393 of 5 stars$14.20-1.6%$37.60+164.8%-71.8%$574.97M$139.93M-17.11220Upcoming EarningsPositive NewsSIBNSI-BONE4.1544 of 5 stars$13.45-2.9%$24.40+81.4%-4.3%$570.99M$167.18M-14.62350Upcoming EarningsNews CoveragePositive NewsAVNSAvanos Medical2.1919 of 5 stars$12.07-2.9%N/A-30.6%$555.26M$687.80M35.504,040Upcoming EarningsShort Interest ↑Analyst RevisionBFLYButterfly Network2.76 of 5 stars$2.27-3.0%$3.00+32.2%+198.6%$551.44M$82.06M-4.93460Insider TradeGap DownCBLLCeriBell2.2181 of 5 stars$14.93+0.5%$32.50+117.7%N/A$535.51M$65.44M0.00N/ANews CoveragePositive NewsKIDSOrthoPediatrics4.1805 of 5 stars$20.52-2.3%$37.00+80.3%-29.7%$498.37M$204.73M-16.68200Upcoming Earnings Related Companies and Tools Related Companies AxoGen Competitors Iradimed Competitors Embecta Competitors Bioventus Competitors RxSight Competitors SI-BONE Competitors Avanos Medical Competitors Butterfly Network Competitors CeriBell Competitors OrthoPediatrics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TLSI Stock Free TLSI Stock Alerts